{
  "title": "Moderna: vaccines, melanoma therapy and cash-flow valuation",
  "asOfDate": "2026-11-03",
  "financialsThrough": "2026-06-30",
  "referenceCloseDate": "2026-11-02",
  "description": "Only research-derived scenario outputs; not issuer filings, clinical source data or investment targets.",
  "units": "USD billions except price and shares",
  "reference": {
    "marketCloseDate": "2026-11-02",
    "marketPriceUsd": 220.83,
    "basicSharesM": 399.24,
    "marketCapB": 88.1641692,
    "financialsThrough": "2026-06-30",
    "q3Reported": false,
    "valuationTimeOrigin": "2026-12-31"
  },
  "reported": {
    "revenueB": {
      "fy2024": 3.236,
      "fy2025": 1.944,
      "h12026": 0.534,
      "ttmJun2026": 2.228
    },
    "productSalesB": {
      "covidFy2025": 1.81,
      "rsvFy2025": 0.008,
      "covidH12026": 0.436,
      "rsvH12026": 0.01
    },
    "h1RegionalProductSalesM": {
      "us2025": 119,
      "eu2025": 0,
      "other2025": 81,
      "us2026": 143,
      "eu2026": 255,
      "other2026": 48
    },
    "ttmJuneCashFlowB": {
      "operatingCash": -1.073,
      "capex": 0.171,
      "cashAfterCapex": -1.244
    },
    "cashJuneB": 6.91,
    "termLoanPrincipalB": 0.6,
    "julyLitigationSettlementB": 0.95
  },
  "financing": {
    "preConvertible2026CashGuidanceLowB": 4.7,
    "preConvertible2026CashGuidanceHighB": 5.2,
    "convertPrincipalB": 3,
    "convertNetProceedsB": 2.9573,
    "cappedCallPremiumB": 0.3288,
    "initialConversionPriceUsd": 210.58,
    "cappedCallCeilingUsd": 392.62,
    "provisionalCash2026EndB": 7.58,
    "provisionalNetFinancialAssetsB": 3.98
  },
  "clinical": {
    "study": "INTerpath-001",
    "patients": 1137,
    "medianFollowUpMonths": 24.6,
    "rfsAt24MonthsPct": {
      "therapyPlusKeytruda": 82.2,
      "keytrudaControl": 70
    },
    "rfsHazardRatio": 0.58,
    "distantMetastasisHazardRatio": 0.62,
    "overallSurvivalMature": false,
    "collaborationProfitShareModernaApproxPct": 50
  },
  "patientAssumptions": {
    "bear": {
      "usEligible": 11200,
      "nonUsEligible": 18400,
      "usPeakPenetrationPct": 20,
      "nonUsPeakPenetrationPct": 10,
      "usNetPriceUsd": 110000,
      "nonUsNetPriceUsd": 70000,
      "worldPeakSalesB": 0.38
    },
    "base": {
      "usEligible": 18000,
      "nonUsEligible": 30000,
      "usPeakPenetrationPct": 45,
      "nonUsPeakPenetrationPct": 25,
      "usNetPriceUsd": 150000,
      "nonUsNetPriceUsd": 95000,
      "worldPeakSalesB": 1.9275
    },
    "bull": {
      "usEligible": 22400,
      "nonUsEligible": 41400,
      "usPeakPenetrationPct": 70,
      "nonUsPeakPenetrationPct": 45,
      "usNetPriceUsd": 200000,
      "nonUsNetPriceUsd": 130000,
      "worldPeakSalesB": 5.56
    }
  },
  "oncologyProgramRnpvB": {
    "bear": {
      "melanoma": -0.32,
      "nsclcResected": -0.45,
      "nsclcOther": -0.36,
      "renalBladder": -0.28
    },
    "base": {
      "melanoma": 1.01,
      "nsclcResected": -0.21,
      "nsclcOther": -0.33,
      "renalBladder": -0.24
    },
    "bull": {
      "melanoma": 5.02,
      "nsclcResected": 1.48,
      "nsclcOther": -0.01,
      "renalBladder": 0.17
    }
  },
  "modelAssumptions": {
    "years": [
      2027,
      2036
    ],
    "oncologyForecastEnds": 2045,
    "oncologyDiscountRatePct": 10.5,
    "longTermTaxPct": 23,
    "stockCompensationTreatedAsExpense": true,
    "oncologyResearchAndCapexAllocatedOnce": true,
    "terminalOnlyOnCorePositiveFcff": true,
    "blackstoneContingentRoyaltiesAndMilestonesIncluded": true,
    "nonOncologyPlatformAssetsNotValued": true
  },
  "scenarios": [
    {
      "id": "bear",
      "name": "Bear",
      "waccPct": 12,
      "growthPct": 0,
      "pvCoreExplicitB": -7.569027,
      "pvCoreTerminalB": 0,
      "oncologyRnpvB": -1.407553,
      "equityValueB": -4.996581,
      "perShareUsd": null,
      "annual": [
        {
          "year": 2027,
          "revenueB": 1.6,
          "coreFcffB": -2.01032,
          "oncologyExpectedFcffB": -0.44,
          "totalIllustrativeFcffB": -2.45032
        },
        {
          "year": 2028,
          "revenueB": 1.31,
          "coreFcffB": -1.9097,
          "oncologyExpectedFcffB": -0.40614,
          "totalIllustrativeFcffB": -2.31584
        },
        {
          "year": 2029,
          "revenueB": 1.305,
          "coreFcffB": -1.62681,
          "oncologyExpectedFcffB": -0.35026,
          "totalIllustrativeFcffB": -1.97706
        },
        {
          "year": 2030,
          "revenueB": 1.3,
          "coreFcffB": -1.36891,
          "oncologyExpectedFcffB": -0.26937,
          "totalIllustrativeFcffB": -1.63829
        },
        {
          "year": 2031,
          "revenueB": 1.31667,
          "coreFcffB": -1.17529,
          "oncologyExpectedFcffB": -0.21849,
          "totalIllustrativeFcffB": -1.39379
        },
        {
          "year": 2032,
          "revenueB": 1.33333,
          "coreFcffB": -0.98668,
          "oncologyExpectedFcffB": -0.1617,
          "totalIllustrativeFcffB": -1.14838
        },
        {
          "year": 2033,
          "revenueB": 1.35,
          "coreFcffB": -0.79306,
          "oncologyExpectedFcffB": -0.10926,
          "totalIllustrativeFcffB": -0.90232
        },
        {
          "year": 2034,
          "revenueB": 1.4,
          "coreFcffB": -0.70283,
          "oncologyExpectedFcffB": -0.08181,
          "totalIllustrativeFcffB": -0.78465
        },
        {
          "year": 2035,
          "revenueB": 1.45,
          "coreFcffB": -0.64261,
          "oncologyExpectedFcffB": -0.0281,
          "totalIllustrativeFcffB": -0.67071
        },
        {
          "year": 2036,
          "revenueB": 1.5,
          "coreFcffB": -0.5674,
          "oncologyExpectedFcffB": 0.00868,
          "totalIllustrativeFcffB": -0.55872
        }
      ]
    },
    {
      "id": "base",
      "name": "Base",
      "waccPct": 10,
      "growthPct": 1.5,
      "pvCoreExplicitB": -2.561682,
      "pvCoreTerminalB": 3.429493,
      "oncologyRnpvB": 0.236988,
      "equityValueB": 5.084799,
      "perShareUsd": 12.736197,
      "annual": [
        {
          "year": 2027,
          "revenueB": 2.5,
          "coreFcffB": -1.609,
          "oncologyExpectedFcffB": -0.44,
          "totalIllustrativeFcffB": -2.049
        },
        {
          "year": 2028,
          "revenueB": 3.02,
          "coreFcffB": -1.0601,
          "oncologyExpectedFcffB": -0.37876,
          "totalIllustrativeFcffB": -1.43886
        },
        {
          "year": 2029,
          "revenueB": 3.51,
          "coreFcffB": -0.71179,
          "oncologyExpectedFcffB": -0.2792,
          "totalIllustrativeFcffB": -0.99099
        },
        {
          "year": 2030,
          "revenueB": 4,
          "coreFcffB": -0.38891,
          "oncologyExpectedFcffB": -0.15464,
          "totalIllustrativeFcffB": -0.54355
        },
        {
          "year": 2031,
          "revenueB": 4.36667,
          "coreFcffB": -0.22672,
          "oncologyExpectedFcffB": -0.06008,
          "totalIllustrativeFcffB": -0.28679
        },
        {
          "year": 2032,
          "revenueB": 4.73333,
          "coreFcffB": 0.00608,
          "oncologyExpectedFcffB": 0.04941,
          "totalIllustrativeFcffB": 0.05549
        },
        {
          "year": 2033,
          "revenueB": 5.1,
          "coreFcffB": 0.11534,
          "oncologyExpectedFcffB": 0.15993,
          "totalIllustrativeFcffB": 0.27527
        },
        {
          "year": 2034,
          "revenueB": 5.66667,
          "coreFcffB": 0.37058,
          "oncologyExpectedFcffB": 0.24545,
          "totalIllustrativeFcffB": 0.61604
        },
        {
          "year": 2035,
          "revenueB": 6.23333,
          "coreFcffB": 0.55223,
          "oncologyExpectedFcffB": 0.33415,
          "totalIllustrativeFcffB": 0.88638
        },
        {
          "year": 2036,
          "revenueB": 6.8,
          "coreFcffB": 0.64492,
          "oncologyExpectedFcffB": 0.39206,
          "totalIllustrativeFcffB": 1.03697
        }
      ]
    },
    {
      "id": "bull",
      "name": "Bull",
      "waccPct": 9,
      "growthPct": 2,
      "pvCoreExplicitB": 8.345557,
      "pvCoreTerminalB": 21.530641,
      "oncologyRnpvB": 6.65674,
      "equityValueB": 40.512938,
      "perShareUsd": 101.475148,
      "annual": [
        {
          "year": 2027,
          "revenueB": 4,
          "coreFcffB": -0.882,
          "oncologyExpectedFcffB": -0.44,
          "totalIllustrativeFcffB": -1.322
        },
        {
          "year": 2028,
          "revenueB": 5.8,
          "coreFcffB": 0.3851,
          "oncologyExpectedFcffB": -0.30686,
          "totalIllustrativeFcffB": 0.07824
        },
        {
          "year": 2029,
          "revenueB": 6.9,
          "coreFcffB": 0.75554,
          "oncologyExpectedFcffB": -0.07406,
          "totalIllustrativeFcffB": 0.68148
        },
        {
          "year": 2030,
          "revenueB": 8,
          "coreFcffB": 1.00783,
          "oncologyExpectedFcffB": 0.18374,
          "totalIllustrativeFcffB": 1.19157
        },
        {
          "year": 2031,
          "revenueB": 9.26667,
          "coreFcffB": 1.52785,
          "oncologyExpectedFcffB": 0.41154,
          "totalIllustrativeFcffB": 1.93939
        },
        {
          "year": 2032,
          "revenueB": 10.53333,
          "coreFcffB": 1.79263,
          "oncologyExpectedFcffB": 0.71087,
          "totalIllustrativeFcffB": 2.50351
        },
        {
          "year": 2033,
          "revenueB": 11.8,
          "coreFcffB": 2.35988,
          "oncologyExpectedFcffB": 1.05487,
          "totalIllustrativeFcffB": 3.41475
        },
        {
          "year": 2034,
          "revenueB": 13.2,
          "coreFcffB": 2.75234,
          "oncologyExpectedFcffB": 1.37387,
          "totalIllustrativeFcffB": 4.1262
        },
        {
          "year": 2035,
          "revenueB": 14.6,
          "coreFcffB": 2.87016,
          "oncologyExpectedFcffB": 1.66369,
          "totalIllustrativeFcffB": 4.53385
        },
        {
          "year": 2036,
          "revenueB": 16,
          "coreFcffB": 3.498,
          "oncologyExpectedFcffB": 1.88905,
          "totalIllustrativeFcffB": 5.38705
        }
      ]
    }
  ],
  "reverse": {
    "priceImpliedOperatingValueB": 84.1841692,
    "required2037CoreFcffB": 19.072445,
    "normalizedBase2036CoreFcffB": 0.74492,
    "requiredExtraPvVersusBaseB": 83.07937,
    "scenarioAssumption": "Base 2027–2036 core cash flows and oncology rNPV fixed; all remaining value attributed to core cash flow after 2036."
  },
  "sensitivity": [
    {
      "waccPct": 8.5,
      "growthPct": 0,
      "perShareUsd": 13.859
    },
    {
      "waccPct": 8.5,
      "growthPct": 1.5,
      "perShareUsd": 16.116
    },
    {
      "waccPct": 8.5,
      "growthPct": 2.5,
      "perShareUsd": 18.248
    },
    {
      "waccPct": 10,
      "growthPct": 0,
      "perShareUsd": 11.34
    },
    {
      "waccPct": 10,
      "growthPct": 1.5,
      "perShareUsd": 12.736
    },
    {
      "waccPct": 10,
      "growthPct": 2.5,
      "perShareUsd": 13.977
    },
    {
      "waccPct": 12,
      "growthPct": 0,
      "perShareUsd": 9.176
    },
    {
      "waccPct": 12,
      "growthPct": 1.5,
      "perShareUsd": 9.977
    },
    {
      "waccPct": 12,
      "growthPct": 2.5,
      "perShareUsd": 10.702
    }
  ],
  "limitations": [
    "2026 year-end cash is a mechanical bridge from July guidance, not updated company guidance.",
    "The market price, current share quote and future year-end net cash are not from a synchronized date.",
    "The zero-coupon convertible note is treated as debt; conversion and capped-call outcomes require separate sensitivity.",
    "Negative bear economic equity is not a negative quoted share price or liquidation appraisal.",
    "Oncology probabilities, commercial pricing and patient eligibility are scenario assumptions, not observed values.",
    "Programs outside the identified modeled pipeline are not valued.",
    "Q3 results scheduled for November 6, 2026 are not included."
  ],
  "sources": [
    {
      "id": "fy2025",
      "title": "Moderna FY2025 Form 10-K",
      "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm"
    },
    {
      "id": "q2filing",
      "title": "Moderna June 2026 Form 10-Q",
      "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm"
    },
    {
      "id": "q2release",
      "title": "Moderna Q2 2026 financial results and guidance",
      "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm"
    },
    {
      "id": "convert",
      "title": "Moderna convertible notes and capped calls, September 2026 Form 8-K",
      "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526378505/d108896d8k.htm"
    },
    {
      "id": "trial",
      "title": "INTerpath-001 Phase 3 melanoma results",
      "url": "https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/"
    },
    {
      "id": "esmo",
      "title": "ESMO commentary on personalized mRNA melanoma Phase 3 data",
      "url": "https://www.esmo.org/insights-by-esmo/all-news/first-positive-phase-iii-trial-data-for-an-individualised-mrna-based-neoantigen-therapy"
    },
    {
      "id": "flu",
      "title": "MFLUSIVA FDA vaccine approval",
      "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva"
    },
    {
      "id": "stock",
      "title": "Moderna historical share price",
      "url": "https://investors.modernatx.com/stock-info"
    },
    {
      "id": "shares",
      "title": "Moderna quoted basic shares outstanding",
      "url": "https://stockanalysis.com/stocks/mrna/statistics/"
    },
    {
      "id": "earnings",
      "title": "Moderna investor events and Q3 2026 earnings schedule",
      "url": "https://investors.modernatx.com/events-presentations"
    },
    {
      "id": "oncology",
      "title": "Moderna oncology investor day presentations",
      "url": "https://investors.modernatx.com/investor-days"
    }
  ]
}
